Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


What Nanotech Means to Health Care Investors

This article was originally published in Start Up

Executive Summary

If there's a common theme being articulated by CEOs of nanobiotechnology start-ups, it's that, at least financially, life has been difficult because they're early stage. Indeed, the nanotech label is less significant to health care investors than considerations related to their business strategy. Drug-delivery-oriented nanobiotechs, for example, must be strongly product focused to avoid the implications that they have an old, low-value model.

Related Content


Related Companies




Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts